Neuroscience
Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL & Alzheimer's Disease Cooperative Study Group. (2009)
Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 72(24):, 2115-2121.
Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
OBJECTIVE: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship. METHODS: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study drug trial of donepezil and vitamin E. Beck Depression Inventory (BDI) was used to assess depressive symptoms at baseline and participants were followed either to the end of study or to the primary endpoint of progression to probable or possible AD. RESULTS: Cox proportional hazards regression, adjusted for age at baseline, gender, apolipoprotein genotype, and NYU paragraph delayed recall score, showed that higher BDI scores were associated with progression to AD (p = 0.03). The sample was stratified into depressed (BDI score > or =10; n = 208) and nondepressed (BDI <10; n = 548) groups. Kaplan-Meier analysis showed that among the depressed subjects, the proportion progressing to AD was lower for the donepezil group than the combined vitamin E and placebo groups at 1.7 years (p = 0.023), at 2.2 years (p = 0.025), and remained marginally lower at 2.7 years (p = 0.070). The survival curves among the three treatment groups did not differ within the nondepressed participants. CONCLUSIONS: Results suggest that depression is predictive of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD) and treatment with donepezil delayed progression to AD among depressed subjects with aMCI. Donepezil appears to modulate the increased risk of AD conferred by the presence of depressive symptoms.
PMID: 19528519 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Amnestic Mild Cognitive Impairment (amci)
Outcome of Mild Cognitive Impairment Comparing Early Memory Profiles. American Journal of Geriatric Psychiatry. 2011 Sep 19; Authors: Gómez-Tortosa E, Mahillo-Fernández I, Guerrero R, Montoya J, Alonso A, Sainz MJ Abstract BACKGROUND:: Finding variables...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, & Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008 Jan 15; 70(3): 191-199. OBJECTIVE: To compare volumetric...
- Neuropsychology Abstract Of The Day: Agitation In Alzheimer's Disease (ad)
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation...
- Abstract Of The Day: Alzheimer Disease
Pavlik VN, Doody RS, Massman PJ, & Chan W. (2006). Influence of premorbid IQ and education on progression of Alzheimer's Disease. Dementia, Geriatrics, & Cognitive Disorders,22(4), 367-377. [Epub ahead of print] Department of Family and Community...
- Abstract Of The Day: Alzheimer Disease
Cummings JL, McRae T, & Zhang R. (2006). Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. American Journal of Geriatric Psychiatry, 14(7), 605-612. Departments of Neurology and Psychiatry and...
Neuroscience
Neuropsychology Abstract of the Day: Donepezil, MCI, and AD
Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL & Alzheimer's Disease Cooperative Study Group. (2009)
Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 72(24):, 2115-2121.
Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
OBJECTIVE: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship. METHODS: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study drug trial of donepezil and vitamin E. Beck Depression Inventory (BDI) was used to assess depressive symptoms at baseline and participants were followed either to the end of study or to the primary endpoint of progression to probable or possible AD. RESULTS: Cox proportional hazards regression, adjusted for age at baseline, gender, apolipoprotein genotype, and NYU paragraph delayed recall score, showed that higher BDI scores were associated with progression to AD (p = 0.03). The sample was stratified into depressed (BDI score > or =10; n = 208) and nondepressed (BDI <10; n = 548) groups. Kaplan-Meier analysis showed that among the depressed subjects, the proportion progressing to AD was lower for the donepezil group than the combined vitamin E and placebo groups at 1.7 years (p = 0.023), at 2.2 years (p = 0.025), and remained marginally lower at 2.7 years (p = 0.070). The survival curves among the three treatment groups did not differ within the nondepressed participants. CONCLUSIONS: Results suggest that depression is predictive of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD) and treatment with donepezil delayed progression to AD among depressed subjects with aMCI. Donepezil appears to modulate the increased risk of AD conferred by the presence of depressive symptoms.
PMID: 19528519 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Amnestic Mild Cognitive Impairment (amci)
Outcome of Mild Cognitive Impairment Comparing Early Memory Profiles. American Journal of Geriatric Psychiatry. 2011 Sep 19; Authors: Gómez-Tortosa E, Mahillo-Fernández I, Guerrero R, Montoya J, Alonso A, Sainz MJ Abstract BACKGROUND:: Finding variables...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, & Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008 Jan 15; 70(3): 191-199. OBJECTIVE: To compare volumetric...
- Neuropsychology Abstract Of The Day: Agitation In Alzheimer's Disease (ad)
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation...
- Abstract Of The Day: Alzheimer Disease
Pavlik VN, Doody RS, Massman PJ, & Chan W. (2006). Influence of premorbid IQ and education on progression of Alzheimer's Disease. Dementia, Geriatrics, & Cognitive Disorders,22(4), 367-377. [Epub ahead of print] Department of Family and Community...
- Abstract Of The Day: Alzheimer Disease
Cummings JL, McRae T, & Zhang R. (2006). Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. American Journal of Geriatric Psychiatry, 14(7), 605-612. Departments of Neurology and Psychiatry and...